Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$907.0K+346.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eyal Shamir
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 68
- Beta
- 0.45
- Country
- IL
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -12.01
Financials
Revenue
$907.0K+346.6%Net Income
$-4.50MEBITDA
$-4.35MFree Cash Flow
$-3.89MEPS (diluted)
$-1.46Shares Outstanding (diluted)
3.09M+1644.1%Operating Expenses
$4.68MCash & Debt
$12.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.38M | $-15.06M | $-7.10 |
| 2024 | $3.29M | $-15.32M | $-9.00 |
| 2023 | $3.23M | $-14.65M | $-9.60 |
| 2022 | $3.08M | $-16.98M | $-13.69 |
| 2021 | $4.14M | $-9.89M | $-10.20 |
| 2020 | $3.87M | $-3.73M | $-8.40 |
| 2019 | $1.66M | $-4.76M | $-10.50 |
| 2018 | $1.07M | $-3.53M | $-9.00 |
| 2017 | $689.4K | $-2.88M | $-13.80 |
| 2016 | $625.5K | $-3.27M | $-18.60 |
| 2015 | $762.9K | $-3.75M | $-24.60 |
| 2014 | $1.07M | $-4.71M | $-110.70 |
| 2013 | $354.6K | $-4.57M | $-231.00 |
Valuation
ICCMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-62.11%Social Signal Score
Mentions (6)
- Newszacks.com·24d ago·Positive
IceCure Secures China NMPA Approval for ProSense Cryoablation System ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
View source ↗ - Newsprnewswire.com·43d ago·Negative
…ieving the highest complete ablation rate among evaluated thermal ablation technologies CAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agreement") with Scovas Medical ("Scovas") for the distribution of …
View source ↗ - Newsprnewswire.com·47d ago·Neutral
…Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approva…
View source ↗ - Newsprnewswire.com·54d ago·Neutral
…cond publication extends cryoablation's clinical role to axillary lymph node metastases CAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation in breast can…
View source ↗ - Newsseekingalpha.com·54d ago·Positive
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·55d ago·Neutral
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position CAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure M
View source ↗
Earnings
Wed, Nov 18(in 6 weeks)
Consensus estimate $-0.83 per share
Typical surprise -6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-1.54 vs $-1.52miss
- Tue, May 12$-1.80 vs $-0.90miss
- Tue, Mar 17$-1.80 vs $-1.20miss
- Wed, Nov 19$-1.80 vs $-1.50miss
- Wed, Aug 13$-1.80 vs $-1.80beat
- Wed, May 28$-1.80 vs $-2.40beat
Estimates and results for ICCM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ICCM officers and directors.
No open-market trades in the recent filings. All 77 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ICCM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.